Taub Rebecca

Director Rebecca Taub sells 2,238 MDGL shares at $490.77; retains 453,351 shares (-0.5% of holdings)

Rebecca Taub, a director of Madrigal Pharmaceuticals, sold 2,238 shares at $490.77 on 2026-01-20, reducing her position from 455,589 to 453,351 shares and generating $1,098,343.26 in proceeds. The sale occurred at a price 2.8% above the current market price of $504.95 and roughly in the middle of the 52-week range of $267.56–$602.83. Taub has a substantial cross-ticker track record of 20 prior open-market sales but has just executed five separate sales at MDGL on 2026-01-09—all prior to this transaction—making this part of an active pattern of liquidation at this ticker over an 11-day window. The company remains unprofitable (net income $-114,190,000.00 for the latest fiscal year) despite $287,268,000.00 in quarterly revenue, presenting a backdrop of fundamental weakness alongside the director's consistent selling activity.

Director Rebecca Taub sold 18,410 shares (18.4K) of MDGL on 2026-01-09 for $9,617,312.09 ($9.6M) at blended price $522.40, reducing stake 3.9%.

Rebecca Taub executed 28 separate sales totaling 18.4K shares for $9.6M at a blended average price of $522.40 on January 9, 2026, reducing her post-transaction holdings to 455.6K shares. The sales occurred across a narrow price range ($512.02–$542.72) and represent a -3.9% reduction in her holdings. At the current price of $493.90, the stock has declined -18.1% from the 52-week high and -13.6% over the prior 30 days, placing the transaction in a period of downward price momentum. Her prior five sales at MDGL (executed on 2025-12-10) all showed negative 30-day returns ranging from -6.2% to -7.2%, indicating a consistent pattern of selling into declines at this specific ticker. Notably, the company reported net income of $-114,190,000.00 for the most recent full fiscal year, highlighting ongoing unprofitability despite $287.3M in quarterly revenue.

Director Taub Rebecca sold 18.6K shares of MDGL for $10.3M (blended avg $552.15) on 2025-12-10.

Taub Rebecca conducted 9 separate sales totaling 18,650 shares for $10,297,572.92 on 2025-12-10, reducing her holdings by 3.9% to 455,589 shares post-transaction. The blended average price of $552.15 was achieved across a narrow range ($547.76–$555.39) within a single trading day. At the current price of $571.44, the stock has risen 8.0% over the past 30 days and 32.2% over 90 days, while her prior sales at MDGL have consistently been followed by gains—her 5 prior trades at this ticker averaged +23.1% at 30 days and +39.4% at 90 days, with zero of those sales proving well-timed (i.e., none were preceded by subsequent declines). Notably, MDGL remains unprofitable, with a net loss of $114.2M against revenue of $287.3M in the latest quarter, yet this sale occurs at a stock price 4.9% below the 52-week high of $601.03.

Director Rebecca Taub sold 46,463 shares in 12 transactions for $16,509,031.66 at MDGL, reducing holdings 9.2%.

Rebecca Taub executed 12 separate sales totaling 46,463 shares for $16,509,031.66 across two trading days (August 11–12, 2025), at a blended average price of $355.32, reducing her holdings by 9.2% from 507,507 shares to 461,044 shares. The stock now trades at $373.46, up 16.8% over the past 30 days and 28.0% over 90 days—prices well above the transaction prices. Taub's cross-ticker track record of 20 prior sells shows an average 90-day return of +12.2% after sells and a 0.00% well-timed rate, indicating her prior sales have been poorly timed, with stocks rising after her exits. The underlying company remains unprofitable, posting a net loss of $42,281,000 on revenue of $212,802,000 in the most recent quarter and negative full-year net income, while market capitalization stands at $8.3B.

Director Rebecca Taub sells 29,101 shares for $10.3M across 9 transactions on July 16-17, reducing holdings 5.9%

Rebecca Taub (Director) executed 9 separate sales totaling 29,101 shares for $10,278,098.15 at blended average price $353.19 on July 16-17, 2025. Post-transaction holdings stand at 461,044 shares, a net reduction of 5.9% versus pre-transaction holdings of 490,145 shares. The sales occurred near the stock's 52-week high of $355.88, with the blended average price $353.19 representing only -6.1% below the year-high water mark. Taub's prior 5 sells at MDGL all executed on 2024-04-08 produced negative 30-day returns (ranging -16.3% to -14.5%) but positive 90-day returns (+11.2% to +13.7%), with 0 of 5 prior trades well-timed at the 90-day mark. Against this ticker-specific history, the current sale's price proximity to the 52-week high—combined with a pattern of prior same-ticker sales that underperformed near-term but recovered over three months—provides context for evaluating the discretionary nature and market conditions of this disposition.